Kornimate/medical-research-clean huggingface dataset:
the effects of using an interactive game with virtual reality for children during intravenous placement

Conditions: Pian; Fear

Summary: to develop the intervention strategies of hospitalized school-age children with iv placement, using interactive virtual reality(vr)as a guiding play and emotional catharsis play, to further examine the effectiveness of reducing iv pain and fear.


Eligibility criteria:
inclusion criteria: * children ages 6-12. * children who where clearly conscious. * children who agreed and were required to receive intravenous injections after physicians' diagnoses. * children and their primary caregivers who could communicate in mandarin or taiwanese * children and their primary caregivers who could read chinese that agreed to participate in this study and sign written consent forms exclusion criteria: * children with developmental delay, epilepsy, or heart diseases * children undergoing chemotherapy; children who were visually or hearing impaired * children who were nearsighted with more than 8.0 diopters or farsighted with 5.0 diopters. * children who had sustained head trauma in the past month * children who were confirmed to be obese according to the recommended body mass index values for children and adolescents * children who required blood transfusions and blood preparation to be performed according to physician diagnoses * children who received two or more intravenous injections and had their blood drawn only one time

Keywords: therapeutic play,virtual reality, intravenous placement, school-age, pain, fear
sirolimus monotherapy in the treatment of antiphospholipid antibody related thrombocytopenia

Conditions: Antiphospholipid (aPL)-Positive; Thrombocytopaenia

Summary: the goal of this clinical trial is to learn the efficacy and safety of sirolimus in the treatment of anti-phospholipid antibody associated thrombocytopenia. the patients would be followed at 2 weeks, 1 month, 3 months, and 6 months after the enrollment. the main questions it aims to answer are the differences between sirolimus and control group at below outcomes: primary outcome: the overall response rate at 6 months secondary outcome: the complete response rate at 6 months the partial response rate at 6 months the change of anti-phospholipid antibody titers participants will receive either sirolimus 1mg per day or placebo.

complete response: the platelet count is more that 100×10\^9/l partial response: if the platelet count is less than 100×10\^9/l, it should be more than 2 times of the baseline count overall response: both complete and partial response

Eligibility criteria:
inclusion criteria: * persistent positive of antiphospholipid antibody (either lupus anticoagulant, anti-cardiolipin antibody, or anti-b2gp1 antibody, at least two times with 12 weeks apart) * persistent thrombocytopenia (30-100×10\^9/l, at least for 2 weeks) * prednisone or equivalent dose less than 10mg per day, and dose stable for more than 2 weeks * hydroxychloroquine less than 400mg per day, and dose stable for more than 1 month * strength of anti-platelet and/or anti-coagulant therapy is stable for 1 week exclusion criteria: * fulling the criteria of other connective tissue disease other than antiphospholipid syndrome * received thrombopoietin or thrombopoietin receptor antagonist within 2 weeks before the enrollment; intravenous immunoglobulin within 1 month before the enrollment; immunosuppressants within 3 months before the enrollment; b cell inhibitors (belimumab or talitacicept) within 3 months before the enrollment; b cell depletion therapy (rituximab) within 6 months before the enrollment. * received oral/intravenous antibiotics within 2 weeks before the enrollment. * new onset of thrombosis within 4 weeks before the enrollment. * apparent bleeding tendency. * life or organ threatening manifestations, includes but not limit to catastrophic antiphospholipid syndrome and thrombotic microangiopathy. * liver and renal dysfunction: alt or ast more than three times of upper limit of normal range; egfr\<40ml/min/1.73m\^2 * hematocytopenia: wbc\<3.0×10\^9/l, hb\<100g/l. * uncontrollable hyperlipidemia: low density lipoprotein cholesterol\>3.1 mmol/l, triglycerides\>2.3 mmol/l after lipid lowering therapy. * current active infection * women in pregnancy and postpartum period

Keywords: antiphospholipid thrombocytopaenia sirolimus rapamycin
comparison of a multiple thrust instrument to a single thrust instrument in treating the low back

Conditions: Low Back Pain

Summary: the purposes of this study are to determine if there is a difference between two treatment methods of spine joints that are not moving as they should as determined by tenderness over the spine and activity of the muscles along side the spine with movement. the hypothesis is that there will be no difference between the two types of treatment.

two specialised instruments used for treating manipulable lesions of the spine will be compared using muscle relaxation response of the erector spinae muscles and correction of the spinal manipulable lesion.

Eligibility criteria:
inclusion criteria: * between 18-64 years of age * fluent in english * with non-specific low back pain * no lumbar manipulation within the prior 24 hours * not involved in strenuous back exercise on the day preceding the study * have not taken pain medication for two days prior to the study exclusion criteria: * absolute contraindications to manipulation * specific causes for the low back pain * involved in or pending litigation for low back pain * lumbar related leg pain

Keywords: low back pain chiropractic manipulation
verification of endotracheal tube placement by ultrasound in the obese patient

Conditions: Intubation, Intratracheal; Obesity

Summary: the purpose of this study is to determine whether verification of correct tube placement after endotracheal intubation in the obese patient can be conducted as fast with ultrasound as with the conventional method of combined auscultation and capnography. the investigators hypothesize that ultrasound is a faster method for verifying correct endotracheal tube placement in the obese patient than combined auscultation and capnography.

both verification methods are conducted in all patients and patients act as their own control

Eligibility criteria:
inclusion criteria: * planned for bariatric surgery in general anaesthesia * planned for endotracheal intubation * bmi above 30 exclusion criteria: * predicted difficult airway in the pre-anaesthesia airway evaluation. * unpredicted difficult airway during induction of anaesthesia where assistance is needed by the investigators.

Keywords: intubation, intratracheal ultrasonography auscultation capnography obesity
amplatzer cardiac plug (acp) registry-long term follow-up protocol

Conditions: Atrial Fibrillation; Left Atrial Appendage; Stroke

Summary: the objective of the amplatzer cardiac plug (acp) registry long term follow-up study is to evaluate long term performance of the acp in closure of the left atrial appendage (laa) in subjects with nonvalvular atrial fibrillation and assess adverse events up to two (2) or more years post implant.


Eligibility criteria:
inclusion criteria: * subject must have a documented history of paroxysmal, persistent or permanent nonvalvular atrial fibrillation (documentation may include an electrocardiogram (ecg), holter, or event recorder) * subject must be ≥18 years of age exclusion criteria: * subject with an implanted atrial septal defect (asd) device or patent foramen ovale (pfo) device * subject who has a history of surgical asd or pfo repair * subject with a history of stroke and unrepaired pfo * subject who has moderate to severe aortic or mitral valve stenosis or regurgitation as assessed by the investigator * subject who has a mitral or aortic prosthetic valve * subject who has a planned ablation procedure for atrial fibrillation 30 days after the acp implant * subject with new york heart association (nyha) grade 4 * subject with evidence of pericardial effusion at baseline evaluation * subject who has complex atheroma with mobile plaque of the descending aorta and/or aortic arch * subject who has an intracardiac thrombus * subject who has carotid disease as assessed by the investigator, requiring treatment, which includes revascularization and/or medical treatment * subject with active infection or active endocarditis * subject who has an acute or recent myocardial infarction (mi) or unstable angina (recent is defined as within 6 months of implant date) * subject who has had recent major cardiac surgical procedure (recent is defined as within 6 months of implant date) * subject with malignancy or other illness where life expectancy is less than one year * subject who is pregnant, breastfeeding, or desires to become pregnant during their first six months of follow-up * subject or legally authorized representative who is unable to provide informed consent * subject who will not be able to be followed for the duration of the clinical study * subject with any medical disorder or severe disability that would interfere with completion or evaluation of clinical study results (for e.g. uncontrolled hypertension, uncontrolled diabetes, renal failure, in situ inferior vena cava (ivc) filter)
self selection trial of naproxen sodium

Conditions: Pain

Summary: a pilot trial to demonstrate that consumers can appropriately select aleve 24 hour for their own use based on expected duration of pain greater than 12 hours.


Eligibility criteria:
inclusion criteria: * at least 12 years of age * report taking at least one dose of over-the-counter (otc) analgesic for pain in the past month * able to read and understand english * provide written informed consent (subjects 12-17 years of age provide written assent and/or parent or legal guardian provide written consent) * provide contact information exclusion criteria: * have participated in a trial involving otc analgesics in the last 6 months * they or someone else in the household work for a market research company, an advertising agency, a public relations firm, a pharmaceutical company, as a healthcare professional, or as part of a health care practice (eliminated for reasons of confidentiality or increased awareness of drugs and their labels) * have a history of known allergies to nonsteroidal antiinflammatory drugs (nsaids) (i.e., naproxen, ibuprofen, acetaminophen, aspirin, etc.) * have a history of heart surgery in the last 60 days or plans for heart surgery in the next 60 days * female subjects who have a positive urine pregnancy test or who are breastfeeding.

Keywords: self selection tria
compassionate use for subcutaneous (sc) belimumab

Conditions: Systemic Lupus Erythematosus

Summary: glaxosmithkline (gsk) have submitted a biologic license application (bla) for the subcutaneous formulation of belimumab which is currently under review by the food and drug administration (fda). the goal of this individual patient compassionate use supply is to provide a patient with subcutaneous belimumab for the period of 1 year or until the subcutaneous formulation of belimumab becomes approved for use by the fda and is commercially available to this patient, whichever is sooner. you can access gsk's policy on compassionate via http://www.gsk.com/media/3368/compassionate-use.pdf.


Eligibility criteria:
this is a protocol to support an emergency ind for compassionate use in one patient requiring use of belimumab subcutaneous for sle treatment (lacks venous access and cannot receive iv belimumab). eligibility criteria is based on the following, as provided within gsk's policy on compassionate use: * the illness being treated is life threatening or seriously debilitating. * there are no satisfactory alternative treatments (confirmed by the hcp). * there is sufficient evidence to believe the benefit to the patient justifies the risk you can access gsk's policy on compassionate via http://www.gsk.com/media/3368/compassionate-use.pdf.

Keywords: subcutaneous belimumab individual patient compassionate use sle gsk1550188
optimisation of hybrid fittings for cochlear implant recipients

Conditions: Hearing Loss

Summary: when providing amplification post-implantation to residual acoustic hearing in the implanted ear, the lower frequency boundary can be modified to minimize or avoid overlap between the frequencies coded through acoustic hearing and those presented through electrical stimulation. this boundary is termed the cross-over frequency (fc) and the effect of modifying this parameter will be investigated in this study. to avoid the research being confounded by prior bias for a particular frequency allocation, the study will be conducted with newly implanted recipients. this study will also investigate whether tests which measure the ability to use low frequency hearing and objective measures can predict the preferred fc and speech performance benefit.


Eligibility criteria:
inclusion criteria: 1. adult (≥18 years of age) 2. post-operative residual hearing in the implanted ear (defined as having an unaided threshold better than or equal to 80 db hl at the 500 hz frequency). 3. implanted with the ci500 or ci24re-series cochlear implants 4. user of the commercially available nucleus 6 sound processor 5. user of the ace strategy 6. native speaker in the language used to assess speech perception performance 7. willingness to participate in and to comply with all requirements of the protocol exclusion criteria: 1. additional handicaps that would prevent participation in evaluations 2. unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedure and investigational device

Keywords: cochlear implants hybrid fittings cross-over frequency
comparison of the visual quality of traditional ultrasound biometrics and lenstar on the cataract after pars plana vitrectomy

Conditions: Diabetic Retinopathy Patients After Vitrectomy

Summary: comparison of the visual quality of traditional ultrasound biometrics and lenstar on the cataract patients with diabetic retinopathy after vitrectomy in the 3 months later.to evaluate the clinical value of lenstar in post-vitrectomy patients.


Eligibility criteria:
inclusion criteria: 1. patients with cataract after vitrectomy because of diabetic retinopathy. 2. patients with good fixation in order to cooperate with various examination. exclusion criteria: 1. myopia of \>6 diopters 2. ocular trauma and other eye disease accepted vitrectomy,such as branch retinal vein occlusion(brvo),central retinal vein occlusion(crvo). 3. vision acuity \<0.1 4. silicone oil eye

Keywords: cataract, higher order aberration,vitrectomy,diabetic retinopathy
pain in traumatic brain injury - basile, md

Conditions: Head Trauma

Summary: the observation through a chart review of persistent pain on neuro psychological functioning and how it applies to the community integration with patients that had suffered traumatic brain injury.

this pilot study is designed and conducted over a one year period by the pi, who then solely carried out this study from recruitment, to patient testing, to data entry. pain was assessed with the visual analog scale and patients underwent a brief battery of tests that included assessment of neuropsychological functions, mood, anxiety and community functions.

Eligibility criteria:
inclusion criteria: * documented history of traumatic brain injury * 18 years or older exclusion criteria: * younger than 18 years old * cannot read and write english

Keywords: head trauma; traumatic brain injury
treatment of vitiligo with low-energy visible light laser

Conditions: Vitiligo

Summary: the purpose of this study is the evaluate the efficacy of using a low-energy 635 nm visible light laser in the treatment of various recalcitrant forms of vitiligo.

vitiligo is a pigmentary disorder characterized by depigmented and hypopigmented macules and patches. there are forms of vitiligo which are more resistant to treatment, including segmental vitiligo and acral vitiligo. previous studies have shown that a low energy helium-neon (633 nm) laser can cause increased proliferation of melanocytes and repigmentation in segmental-type vitiligo. the goal of this study is to verify these results and show efficacy in other recalcitrant forms of vitiligo including acral vitiligo and post melanocyte-keratinocyte transplantation vitiligo.

Eligibility criteria:
inclusion criteria: * be at least 18 years old * have active or stable segmental vitiligo on the neck or face, acral vitiligo, or have undergone recent melanocyte-keratinocyte transplantation procedure (mktp) * agree to abide by the investigator's guidelines regarding photosensitizing drugs and photoprotection * be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form * agree to follow and undergo all study-related procedures exclusion criteria: * women who are lactating, pregnant, or planning to become pregnant * patients with a recent history of melasma, and other disorders of pigmentation with the exception of post inflammatory hyperpigmentation * patients with a known history of photosensitivity disorders * photosensitizing medications may be continued throughout of the study at the discretion of the investigator * patients with a known history of melanoma or non-melanoma skin cancers * concomitant use of tanning beds * any reason the investigator feels the patient should not participate in the study

Keywords: vitiligo laser segmental vitiligo acral vitiligo
defocus induced changes on choroidal thickness

Conditions: Induced Defocus to the Retina

Summary: the goals of this study are to assess the short-term (10-60 minutes) effects of different magnitudes of myopic and hyperopic optical defocus on the transient thickness of the choroid in children and adults, as well as to assess the recovery period. choroidal thickness will be measured non-invasively following 10-60 minutes of monocular exposure to -5 diopters to +5 diopters of optical defocus induced by spectacle lenses. the hypothesis is that choroidal thickness will increase with increasing myopic defocus and decrease with increasing hyperopic defocus. the relationship between the magnitude of defocus and the magnitude and direction of choroidal thickness change will be assessed.

the purpose of this study is to determine modifying factors inducing or protecting against the development or progression of myopia, or nearsightedness. myopia has reached epidemic levels in urbanized countries, reaching up to 90% of the teenage and young adult population in urban asia. myopia represents a significant socioeconomic burden and poses a risk for associated ocular diseases such as retinal detachment, choroidal neovascularization, and glaucoma. the economic and public health burden of myopia are growing disproportionately to the population, spurring interest in the development of therapies to prevent occurrence or progression. myopia generally occurs because the eye grows too long, with onset and progression occurring from about ages 6 to 20. though much is known about factors that influence eye growth, the exact mechanisms by which they do so have not been elucidated. the goals of this study are to assess the short-term (10-50 minutes) effects of different magnitudes of myopic and hyperopic optical defocus on the transient thickness of the choroid in children and adults, as well as to assess the recovery period. choroidal thickness will be measured non-invasively following 10-50 minutes of monocular exposure to -5d to +5d of optical defocus induced by spectacle lenses. the hypothesis is that choroidal thickness will increase with increasing myopic defocus and decrease with increasing hyperopic defocus. the relationship between the magnitude of defocus and the magnitude and direction of choroidal thickness change will be assessed.

Eligibility criteria:
inclusion criteria: * 6 to 45 years of age (preliminary studies indicate that children under 6 cannot sit for imaging, and subjects over 45 do not respond to the optical defocus with expected choroidal thickness changes) * best corrected visual acuity of 20/25 or better in better-seeing eye exclusion criteria: * age younger than 6 years or older than 45 * best corrected visual acuity worse than 20/25 in better-seeing eye * ocular pathology or prior ocular injury * heavily-pigmented choroid that precludes accurate measurement of choroidal thickness

Keywords: myopia choroid retina blur defocus eye growth
propranolol hydrochloride in treating patients with prostate cancer undergoing surgery

Conditions: Prostate Carcinoma

Summary: this randomized pilot clinical trial studies how well propranolol hydrochloride works in treating patients with prostate cancer who are undergoing surgery. when stressed, the body makes a molecule that may prevent tumor cells from dying, and propranolol hydrochloride may affect the signals in cells that cause tumor cells survival and death.

primary objectives: i. to compare activation of adrb2/pka/bad signaling pathway in the prostate glands of men two hours after taking or not taking propranolol hydrochloride (propranolol) prior to prostatectomy, as indicated by phosphorylated creb. secondary objectives: i. to compare activation of adrb2/pka/bad signaling pathway in the prostate glands of men two hours after taking or not taking propranolol prior to prostatectomy as indicated by phosphorylated bad. ii. to determine the difference in candidate transcript levels associated with adrb2/pka activation between individuals two hours after taking propranolol or not taking propranolol prior to prostatectomy. iii. to determine plasma propranolol levels in individuals taking propranolol two hours after administration prior to prostatectomy. iv. to determine if plasma catecholamine levels in men with prostate cancer can be used as a biomarker to identify patients who show activation of adrb2 signaling pathway in prostate tumors. v. to determine perceived stress level differences in men with prostate cancer prior to surgery to examine possible association between perceived stress level and catecholamine levels in blood and activation of adrb2 pathway in tumors. vi. to determine perceived distress level differences in men with prostate cancer prior to surgery to examine possible association between distress level and catecholamine levels in blood and activation of adrb2 pathway tumors. outline: patients are randomized into 1 of 2 groups. group i: patients receive propranolol hydrochloride orally (po) 2 hours prior to standard of care prostatectomy. group ii: patients receive no treatment prior to standard of care prostatectomy. after completion of study treatment, patients are followed up for 30 days.

Eligibility criteria:
inclusion criteria: * diagnosis of prostate cancer undergoing prostatectomy * individuals able to understand and willing to sign an institutional review board (irb)-approved informed consent document exclusion criteria: * men taking propranolol on a daily for any reason are excluded * men with baseline systolic blood pressure (sbp) \< 110 or heart rate (hr) \< 60 * men unable to swallow pills * history of current or past medical or psychiatric illness that would make participation difficult or not feasible at the discretion of the principal investigator or co-investigators